Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024-01 · 22 (1D) · 1-19
DOI: 10.6004/jnccn.2024.0001 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-01. Verfasst von Shaji K Kumar und 35 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mayo Clinic Comprehensive Cancer Center.
- University of Wisconsin Carbone Cancer Center.
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
- UT Southwestern Simmons Comprehensive Cancer Center.
- Vanderbilt-Ingram Cancer Center.
- Moffitt Cancer Center.
Zitieren
APA
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., …, & Kumar, R. (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(1D), 1-19. https://doi.org/10.6004/jnccn.2024.0001
Vancouver
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2024;22(1D):1-19. doi:10.6004/jnccn.2024.0001
BibTeX
@article{Kumar2024,
author = {Kumar, Shaji K and Callander, Natalie S and Adekola, Kehinde and Anderson, Larry D and Baljevic, Muhamed and Baz, Rachid and Campagnaro, Erica and Castillo, Jorge J and Costello, Caitlin and D'Angelo, Christopher and Derman, Benjamin and Devarakonda, Srinivas and Elsedawy, Noura and Garfall, Alfred and Godby, Kelly and Hillengass, Jens and Holmberg, Leona and Htut, Myo and Huff, Carol Ann and Hultcrantz, Malin and Kang, Yubin and Larson, Sarah and Lee, Hans and Liedtke, Michaela and Martin, Thomas and Omel, James and Robinson, Timothy and Rosenberg, Aaron and Sborov, Douglas and Schroeder, Mark A and Sherbenou, Daniel and Suvannasankha, Attaya and Valent, Jason and Varshavsky-Yanovsky, Asya Nina and Snedeker, Jenna and Kumar, Rashmi},
title = {Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
volume = {22},
number = {1D},
pages = {1--19},
doi = {10.6004/jnccn.2024.0001}
}
EUVIMED